Open trial of mirtazapine in patients with fibromyalgia
Some positive therapeutic effects in fibromyalgia syndrome (FS) were reported with both tricyclic and new antidepressant drugs as well as serotonergic agents (5HT2 and 5HT3 receptor blockers). In the present study, a novel antidepressant drug mirtazapine, 15-30 mg/day, has been used in 29 patients w...
Gespeichert in:
| Veröffentlicht in: | Pharmacopsychiatry 2004-07, Vol.37 (4), p.168-170 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 170 |
|---|---|
| container_issue | 4 |
| container_start_page | 168 |
| container_title | Pharmacopsychiatry |
| container_volume | 37 |
| creator | Samborski, W Lezanska-Szpera, M Rybakowski, J K |
| description | Some positive therapeutic effects in fibromyalgia syndrome (FS) were reported with both tricyclic and new antidepressant drugs as well as serotonergic agents (5HT2 and 5HT3 receptor blockers).
In the present study, a novel antidepressant drug mirtazapine, 15-30 mg/day, has been used in 29 patients with FS in an open trial.
Twenty-six patients completed the six-week study. Ten (38%) were considered responders on account of the reduction of > or =40% on pain, fatigue and sleep disturbances and remission of depressive symptoms at the end of study. Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms. Reduction on main symptoms of FS after 6 weeks of mirtazapine treatment significantly correlated with the reduction in depression. However, the percentage of responders and patients with > or = 40% reduction on main symptoms of fibromyalgia was similar in high and low depression groups.
The results obtained suggest that mirtazapine may be promising method of FS treatment. Further double-blind placebo-controlled studies are required to confirm these results. |
| doi_str_mv | 10.1055/s-2004-827172 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_66984975</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66984975</sourcerecordid><originalsourceid>FETCH-LOGICAL-c276t-b2d4dfb644e2612dadf20cfeba2ad8dbc873d6573709100fba1b43aab163a03f3</originalsourceid><addsrcrecordid>eNo1j0tLAzEURrNQbK0u3UpW7qI3j0lmllJ8QaEbXQ83k0Qj8zJJkfrrLVhXBz4OHxxCrjjccqiqu8wEgGK1MNyIE7IEbjST2jQLcp7zJwBXDcgzsuCVOqxGLonZzn6kJUXs6RToEFPBH5zj6Gkc6Ywl-rFk-h3LBw3RpmnYY_8e8YKcBuyzvzxyRd4eH17Xz2yzfXpZ329YJ4wuzAqnXLBaKS80Fw5dENAFb1Ggq53taiOdrow00HCAYJFbJREt1xJBBrkiN3-_c5q-dj6Xdoi5832Po592udW6qVVjqoN4fRR3dvCunVMcMO3b_1T5C8QdU-k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66984975</pqid></control><display><type>article</type><title>Open trial of mirtazapine in patients with fibromyalgia</title><source>MEDLINE</source><source>Thieme Connect Journals</source><creator>Samborski, W ; Lezanska-Szpera, M ; Rybakowski, J K</creator><creatorcontrib>Samborski, W ; Lezanska-Szpera, M ; Rybakowski, J K</creatorcontrib><description>Some positive therapeutic effects in fibromyalgia syndrome (FS) were reported with both tricyclic and new antidepressant drugs as well as serotonergic agents (5HT2 and 5HT3 receptor blockers).
In the present study, a novel antidepressant drug mirtazapine, 15-30 mg/day, has been used in 29 patients with FS in an open trial.
Twenty-six patients completed the six-week study. Ten (38%) were considered responders on account of the reduction of > or =40% on pain, fatigue and sleep disturbances and remission of depressive symptoms at the end of study. Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms. Reduction on main symptoms of FS after 6 weeks of mirtazapine treatment significantly correlated with the reduction in depression. However, the percentage of responders and patients with > or = 40% reduction on main symptoms of fibromyalgia was similar in high and low depression groups.
The results obtained suggest that mirtazapine may be promising method of FS treatment. Further double-blind placebo-controlled studies are required to confirm these results.</description><identifier>ISSN: 0176-3679</identifier><identifier>DOI: 10.1055/s-2004-827172</identifier><identifier>PMID: 15467973</identifier><language>eng</language><publisher>Germany</publisher><subject>Adrenergic alpha-Antagonists - administration & dosage ; Adrenergic alpha-Antagonists - therapeutic use ; Adult ; Depression - diagnosis ; Depression - drug therapy ; Depression - etiology ; Drug Administration Schedule ; Female ; Fibromyalgia - diagnosis ; Fibromyalgia - drug therapy ; Fibromyalgia - psychology ; Humans ; Male ; Mianserin - administration & dosage ; Mianserin - analogs & derivatives ; Mianserin - therapeutic use ; Middle Aged ; Severity of Illness Index</subject><ispartof>Pharmacopsychiatry, 2004-07, Vol.37 (4), p.168-170</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c276t-b2d4dfb644e2612dadf20cfeba2ad8dbc873d6573709100fba1b43aab163a03f3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15467973$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Samborski, W</creatorcontrib><creatorcontrib>Lezanska-Szpera, M</creatorcontrib><creatorcontrib>Rybakowski, J K</creatorcontrib><title>Open trial of mirtazapine in patients with fibromyalgia</title><title>Pharmacopsychiatry</title><addtitle>Pharmacopsychiatry</addtitle><description>Some positive therapeutic effects in fibromyalgia syndrome (FS) were reported with both tricyclic and new antidepressant drugs as well as serotonergic agents (5HT2 and 5HT3 receptor blockers).
In the present study, a novel antidepressant drug mirtazapine, 15-30 mg/day, has been used in 29 patients with FS in an open trial.
Twenty-six patients completed the six-week study. Ten (38%) were considered responders on account of the reduction of > or =40% on pain, fatigue and sleep disturbances and remission of depressive symptoms at the end of study. Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms. Reduction on main symptoms of FS after 6 weeks of mirtazapine treatment significantly correlated with the reduction in depression. However, the percentage of responders and patients with > or = 40% reduction on main symptoms of fibromyalgia was similar in high and low depression groups.
The results obtained suggest that mirtazapine may be promising method of FS treatment. Further double-blind placebo-controlled studies are required to confirm these results.</description><subject>Adrenergic alpha-Antagonists - administration & dosage</subject><subject>Adrenergic alpha-Antagonists - therapeutic use</subject><subject>Adult</subject><subject>Depression - diagnosis</subject><subject>Depression - drug therapy</subject><subject>Depression - etiology</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Fibromyalgia - diagnosis</subject><subject>Fibromyalgia - drug therapy</subject><subject>Fibromyalgia - psychology</subject><subject>Humans</subject><subject>Male</subject><subject>Mianserin - administration & dosage</subject><subject>Mianserin - analogs & derivatives</subject><subject>Mianserin - therapeutic use</subject><subject>Middle Aged</subject><subject>Severity of Illness Index</subject><issn>0176-3679</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j0tLAzEURrNQbK0u3UpW7qI3j0lmllJ8QaEbXQ83k0Qj8zJJkfrrLVhXBz4OHxxCrjjccqiqu8wEgGK1MNyIE7IEbjST2jQLcp7zJwBXDcgzsuCVOqxGLonZzn6kJUXs6RToEFPBH5zj6Gkc6Ywl-rFk-h3LBw3RpmnYY_8e8YKcBuyzvzxyRd4eH17Xz2yzfXpZ329YJ4wuzAqnXLBaKS80Fw5dENAFb1Ggq53taiOdrow00HCAYJFbJREt1xJBBrkiN3-_c5q-dj6Xdoi5832Po592udW6qVVjqoN4fRR3dvCunVMcMO3b_1T5C8QdU-k</recordid><startdate>20040701</startdate><enddate>20040701</enddate><creator>Samborski, W</creator><creator>Lezanska-Szpera, M</creator><creator>Rybakowski, J K</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20040701</creationdate><title>Open trial of mirtazapine in patients with fibromyalgia</title><author>Samborski, W ; Lezanska-Szpera, M ; Rybakowski, J K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c276t-b2d4dfb644e2612dadf20cfeba2ad8dbc873d6573709100fba1b43aab163a03f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adrenergic alpha-Antagonists - administration & dosage</topic><topic>Adrenergic alpha-Antagonists - therapeutic use</topic><topic>Adult</topic><topic>Depression - diagnosis</topic><topic>Depression - drug therapy</topic><topic>Depression - etiology</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Fibromyalgia - diagnosis</topic><topic>Fibromyalgia - drug therapy</topic><topic>Fibromyalgia - psychology</topic><topic>Humans</topic><topic>Male</topic><topic>Mianserin - administration & dosage</topic><topic>Mianserin - analogs & derivatives</topic><topic>Mianserin - therapeutic use</topic><topic>Middle Aged</topic><topic>Severity of Illness Index</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Samborski, W</creatorcontrib><creatorcontrib>Lezanska-Szpera, M</creatorcontrib><creatorcontrib>Rybakowski, J K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmacopsychiatry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Samborski, W</au><au>Lezanska-Szpera, M</au><au>Rybakowski, J K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Open trial of mirtazapine in patients with fibromyalgia</atitle><jtitle>Pharmacopsychiatry</jtitle><addtitle>Pharmacopsychiatry</addtitle><date>2004-07-01</date><risdate>2004</risdate><volume>37</volume><issue>4</issue><spage>168</spage><epage>170</epage><pages>168-170</pages><issn>0176-3679</issn><abstract>Some positive therapeutic effects in fibromyalgia syndrome (FS) were reported with both tricyclic and new antidepressant drugs as well as serotonergic agents (5HT2 and 5HT3 receptor blockers).
In the present study, a novel antidepressant drug mirtazapine, 15-30 mg/day, has been used in 29 patients with FS in an open trial.
Twenty-six patients completed the six-week study. Ten (38%) were considered responders on account of the reduction of > or =40% on pain, fatigue and sleep disturbances and remission of depressive symptoms at the end of study. Eighteen patients had at least moderate depression before mirtazapine treatment and 8 patients presented mild depressive symptoms. Reduction on main symptoms of FS after 6 weeks of mirtazapine treatment significantly correlated with the reduction in depression. However, the percentage of responders and patients with > or = 40% reduction on main symptoms of fibromyalgia was similar in high and low depression groups.
The results obtained suggest that mirtazapine may be promising method of FS treatment. Further double-blind placebo-controlled studies are required to confirm these results.</abstract><cop>Germany</cop><pmid>15467973</pmid><doi>10.1055/s-2004-827172</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0176-3679 |
| ispartof | Pharmacopsychiatry, 2004-07, Vol.37 (4), p.168-170 |
| issn | 0176-3679 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_66984975 |
| source | MEDLINE; Thieme Connect Journals |
| subjects | Adrenergic alpha-Antagonists - administration & dosage Adrenergic alpha-Antagonists - therapeutic use Adult Depression - diagnosis Depression - drug therapy Depression - etiology Drug Administration Schedule Female Fibromyalgia - diagnosis Fibromyalgia - drug therapy Fibromyalgia - psychology Humans Male Mianserin - administration & dosage Mianserin - analogs & derivatives Mianserin - therapeutic use Middle Aged Severity of Illness Index |
| title | Open trial of mirtazapine in patients with fibromyalgia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T21%3A49%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Open%20trial%20of%20mirtazapine%20in%20patients%20with%20fibromyalgia&rft.jtitle=Pharmacopsychiatry&rft.au=Samborski,%20W&rft.date=2004-07-01&rft.volume=37&rft.issue=4&rft.spage=168&rft.epage=170&rft.pages=168-170&rft.issn=0176-3679&rft_id=info:doi/10.1055/s-2004-827172&rft_dat=%3Cproquest_pubme%3E66984975%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=66984975&rft_id=info:pmid/15467973&rfr_iscdi=true |